CriticalAntiviral for systemic use, HIV-1 protease inhibitor; used only with a pharmacokinetic booster (ritonavir or cobicistat)×Reversible P2Y12 receptor inhibitor
Updated · Methodology
Mechanism
CYP3A4 is the main enzyme that metabolises ticagrelor, and ticagrelor is a substrate of the transporter P-glycoprotein (P-gp) (ticagrelor summary of product characteristics, SmPC, European Medicines Agency, EMA). Darunavir is always taken with a booster (low-dose ritonavir or cobicistat), and both boosters inhibit the enzyme CYP3A (darunavir SmPC, EMA). According to the darunavir documents, boosted darunavir may raise ticagrelor levels by inhibiting CYP3A and P-gp, although this has not been studied directly (darunavir SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). For comparison, ketoconazole, a strong CYP3A4 inhibitor, raised the peak ticagrelor concentration 2.4-fold and the area under the concentration–time curve (AUC) 7.3-fold (EMA). According to the US ticagrelor label, strong CYP3A inhibitors substantially increase ticagrelor exposure and with it the risk of dyspnoea, bleeding and other adverse events (ticagrelor label, US Food and Drug Administration, FDA).
Symptoms
Higher ticagrelor levels increase the risk of bleeding, dyspnoea and other adverse events (ticagrelor label, US Food and Drug Administration, FDA). Signs of bleeding include bruising, nosebleeds, bleeding that is hard to stop, urine that is pink, red or brown, vomiting blood or material that looks like coffee grounds, red or black tarry stools and coughing up blood (FDA). Dyspnoea with ticagrelor is usually mild to moderate and often resolves without stopping treatment (ticagrelor summary of product characteristics, SmPC, European Medicines Agency, EMA). Ventricular pauses, mostly without symptoms, were recorded more often with ticagrelor than with clopidogrel. Post-marketing reports describe bradyarrhythmias, including atrioventricular block (EMA; FDA).
Management
The combination is contraindicated. The European darunavir summary of product characteristics (SmPC) names ticagrelor among the drugs that must not be given with darunavir boosted with either ritonavir or cobicistat (darunavir SmPC, European Medicines Agency, EMA; darunavir SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The same contraindication appears in the SmPCs of the darunavir/cobicistat tablets (SmPCs of these products, EMA). The ticagrelor SmPC, in turn, contraindicates strong CYP3A4 inhibitors and names ritonavir among them. Darunavir is never used without ritonavir or cobicistat (ticagrelor and darunavir SmPCs, EMA). The US documents are less strict: the darunavir labels do not recommend ticagrelor with darunavir/ritonavir or darunavir/cobicistat, and the ticagrelor label says to avoid strong CYP3A inhibitors, including ritonavir (darunavir and ticagrelor labels, US Food and Drug Administration, FDA). If a person taking darunavir needs an antiplatelet drug, the darunavir/cobicistat SmPC recommends agents not affected by CYP inhibition or induction, such as prasugrel (EMA). The US darunavir label requires no prasugrel dose adjustment with darunavir/ritonavir (FDA). The documents do not recommend clopidogrel with boosted darunavir either, because darunavir may lower the levels of the clopidogrel active metabolite and its antiplatelet effect (AEMPS; FDA). In people treated for coronary artery disease, stopping ticagrelor increases the risk of myocardial infarction, stroke and death (ticagrelor FDA label). The documents do not give an interval between the last dose of one drug and the start of the other.
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Brilinta (ticagrelor) tablets – prescribing information (2026)– AstraZeneca Pharmaceuticals LP. Brilinta prescribing information, revised 05/2026, sections 2.1, 2.2, 7.1, 7.2, 7.4, 7.5, 14.1 and 17. DailyMed setid f7b3f443-e83d-4bf2-0e96-023448fed9a8
- FDA: Prezista (darunavir) prescribing information (2025)– FDA, DailyMed, setid 814301f9-c990-46a5-b481-2879a521a16f, SPL 08/2025 (Revised 03/2023), sections 4 and 7 (Table 10)
- EMA: Ficha técnica: Darunavir (Prezista, EU/1/06/380), sección 4.3 (2026)– EMA SmPC vía AEMPS CIMA, nº 106380007 (EU/1/06/380), secciones 4.3 y 4.5, consultado 10/2026
- EMA: Ficha técnica: Ticagrelor, Brilique (EU/1/10/655), secciones 4.3 y 4.5 (2026)– EMA, SmPC Brilique 90 mg comprimidos, EU/1/10/655, texto en CIMA nº registro 10655004, consultado 11.10.2026, sin fecha de revisión en CIMA, secciones 4.3, 4.4 y 4.5
- EMA: Ficha técnica: Darunavir/cobicistat (EU/1/14/967), sección 4.5 (2026)– EMA, Rezolsta 800 mg/150 mg (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 114967001, consultada 10/2026, secciones 4.3 y 4.5
- AEMPS: Ficha técnica: Darunavir (Darunavir Aurovitas, nº registro 84835), sección 4.5 (2023)– AEMPS, CIMA, nº registro 84835, revisión 09/2023, secciones 4.3 y 4.5
- FDA: PREZCOBIX (darunavir and cobicistat) prescribing information (2026)– FDA, DailyMed setid 9c38fdb6-d0ba-4f16-a0e3-85d9ec334d9f (Janssen Products), revisión 02/2026 (versión 29), secciones 4, 6.2, 7.1 y 7.3